平安证券（香港）港股晨报-20260210

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61%, and the Hang Seng China Enterprises Index at 9,656 points, down 47 points or 0.49% [1][5] - On a previous trading day, the market saw a significant rise, with the Hang Seng Index increasing by 1.76% to 27,027.16 points, and a total market turnover of HKD 255.14 billion [1][5] - The net inflow of funds through the Hong Kong Stock Connect reached HKD 4.84 billion, with the Shanghai and Shenzhen Connects contributing HKD 2.83 billion and HKD 2.01 billion respectively [1][5] Key Companies and Performance - Notable gainers included Pop Mart, which rose by 5.76%, and Zijin Mining, which increased by 5.58%. China Ping An also saw a rise of 4.89% [1][5] - Conversely, China Telecom and Kuaishou saw declines of 2.96% and 2.74% respectively [1][5] - In the US market, tech stocks drove gains, with the Nasdaq rising by 0.9% to 23,238 points, and Nvidia and Broadcom showing strong performances with increases of 2.5% and 3.3% respectively [2] Industry Insights - The report emphasizes the importance of "technological self-reliance" and AI applications as core themes for future developments in the Hong Kong stock market, suggesting that leading companies in these sectors may benefit from long-term growth opportunities [3] - The Ministry of Industry and Information Technology's recent policy guidance on building national computing power interconnectivity nodes is expected to boost domestic computing and communication sectors [3] - The report recommends focusing on sectors supported by policies aimed at expanding domestic consumption, such as sports apparel and non-essential services, as well as undervalued central state-owned enterprises with high dividend yields [3] Market Trends - The report indicates that both the Hong Kong and A-share markets started the year positively, with a net inflow of HKD 69 billion from southbound funds in January [3] - The report highlights the potential for growth in the Chinese medicine industry, driven by a new development plan aimed at enhancing the entire industry chain by 2030 [9]